MedTrace Logo

Effect of Dexmedetomidine on Acute Kidney Injury After Ascending Aortic Surgeries

NCT06958367 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-05-07

No results posted yet for this study

Summary

Acute kidney injury (AKI) is a frequent and serious complication after ascending aortic surgeries requiring cardiopulmonary bypass (CPB). Dexmedetomidine, a selective α-2 adrenoreceptor agonist, may reduce AKI because of its sympatholytic and anti-inflammatory effects against ischaemia reperfusion injury. We investigate the effect of dexmedetomidine administration on AKI after ascending aortic surgeries requiring CPB in a placebo-controlled randomised controlled trial.

Conditions

  • Aki After Ascending Aortic Surgeries

Interventions

DRUG

Dexmedetomidine

the effect of dexmedetomidine administration on AKI after ascending aortic surgeries requiring CPB in a placebo-controlled randomised controlled trial.

DRUG

Normal Saline (Placebo)

Group (B): the control group will receive an infusion of an equivalent volume of a 0.9% saline for the same duration

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • galal EL-KADY, MD · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2026-05-02
Completion
2026-05-03

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06958367 on ClinicalTrials.gov